NVP-BHG712

Catalog No.S2202

NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition; also shows activity against c-Raf, c-Src and c-Abl with IC50 of 0.395 μM, 1.266 μM and 1.667 μM, respectively.

Price Stock Quantity  
USD 340 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

NVP-BHG712 Chemical Structure

NVP-BHG712 Chemical Structure
Molecular Weight: 503.48

Validation & Quality Control

1 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Product Information

  • Compare Ephrin receptor Inhibitors
    Compare Ephrin receptor Products
  • Research Area
  • Inhibition Profile

Product Description

Biological Activity

Description NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition; also shows activity against c-Raf, c-Src and c-Abl with IC50 of 0.395 μM, 1.266 μM and 1.667 μM, respectively.
Targets EphB4 [1] C-Raf [1] c-Src [1] c-Abl [1]

 View  More

IC50 25 nM(ED50) 0.395 μM 1.266 μM 1.667 μM
In vitro NVP-BHG712 treatment also dose dependently leads to the inhibition of RTK autophosphorylation in stable transfected A375 melanoma cells with EC50 of 25 nM and 4.2 μM for EphB4 and VEGFR2, respectively. [1]
In vivo In a growth factor-induced angiogenesis model, NVP-BHG712 (3 mg/kg, p.o) significantly suppresses VEGF stimulated tissue formation and vascularization by inhibiting EphB4 forward signaling. Furthermore, NVP-BHG712 (10 mg/kg/kg, p.o.) potently reverses VEGF enhanced tissue formation and vessel growth. NVP-BHG712 (3 mg/kg, p.o.) shows a long lasting exposure with concentrations around 10 μM in plasma as well as in lung and liver tissue for up to 8 hours, and thus results in a long lasting inhibition of EphB4 kinase activity in mice. [1]
Features Discriminates between VEGFR and EphB4.

Protocol(Only for Reference)

Kinase Assay: [1]

In vitro kinase assays All in vitro kinase assays are performed with recombinant purified kinases either purchased from external vendors or produced in house. To estimate kinase activity both, TR-FRET-based LanthaScreenTM and Caliper mobility shift are used. In brief, the LanthaScreenTM assay technology is based on the discrimination between the unphosphorylated substrate and the phosphorylated product by a phospho-specific antibody, binding only to the phosphorylated version of the substrate. Both, antibody and substrate, carry fluorescent labels and the close proximity of the labels in the formed complex allows the measurement of a fluorescence resonance energy transfer (FRET) signal. Reading of the FRET signal in a time-dependent/time-gated manner further improves the assay performance by reducing background fluorescence. For dose–response measurements NVP-BHG712 is pre-diluted in 90% DMSO and 50 nL of compound solutions are dispensed directly into the empty assay plate using a HummingBird nanodispenser. The kinase reactions are started by addition of 4.5 μL ATP solution (4 μM ATP, 20 mM Tris/HCL, 1 mM DTT, 0.03% Tween20, 0.01 mM Na3VO4) and 4.5 μL enzyme/substrate mix (100 nM fluorescein poly-GAT), 0.5% bovine serum albumin, 20 mM Tris/HCL, 1 mM DTT, 0.03% Tween20, 0.01 mM Na3VO4). Further components of the enzyme/substrate mix are the enzymes as well as MgCl2/MnCl2 which are adjusted specifically to the requirements of the individual enzyme. After incubation for 60 minutes at r.t. the kinase reactions are stopped by addition of 4.5 μL stop solution (50 mM EDTA pH 8.0, 0.04% NP-40, 20 mM Tris/HCl pH 7.4) followed by 4.5 μL of detection mix (1.72 μg/mL Tb-PY20 antibody), 1% bovine serum albumin, 20 mM Tris/HCl, 1 mM DTT, 0.03% Tween20, 0.01 mM Na3VO4). After incubation for 45 minutes at r.t. plates are analyzed in a BMG PHERAstar plate reader. In the Caliper mobility shift assays kinase reactions are analyzed by microfluidic capillary electrophoresis. The transfer of phosphate from ATP to a short peptide by a kinase causes a change in the net-charge of the peptide by −2. The charge difference between the unphosphorylated and phosphorylated entities of the peptide can be separated in an electrical field. Using peptides attached with a fluorescent label allows detection and quantification of both forms and hence the calculation of the reaction turnover. For dose–response measurements NVP-BHG712 is pre-diluted in 90% DMSO and 50 nL aliquots of solution are dispensed directly into the empty assay plate using a HummingBird nanodispenser. The kinase reactions are started by addition of 4.5 μL substrate mix consisting of ATP and peptide substrate in assay buffer (50 mM HEPES pH 7.5, 0.02% bovine serum albumin, 1 mM DTT, 0.02% Tween20, 0.01 mM Na34, 10 mM beta-glycerophosphate) and 4.5 μL enzyme solution in assay buffer. The peptide concentration is 2 μM in the assays. Concentrations for the enzyme, as well as for MgCl2 and MnCl2 are adjusted specifically to the requirements of the individual enzyme. ATP concentrations are adjusted to the Km values of the specific enzyme. After incubation for 60 minutes at 30 °C the kinase reactions are stopped by addition of 16 μL stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% coating reagent 10 mM EDTA pH 8.0, 0.015% BRIJ35). Stopped kinase reactions are analyzed in a LC3000 reader.

Animal Study: [1]

Animal Models VEGF-mediated angiogenesis in vivo is induced in a growth factor implant model in mice.
Formulation NVP-BHG712 is dissolved in 1-Methyl-2-pyrrolidone (NMP) and then diluted with polyethylene glycol 300 (PEG300) to a final concentration of 10% v/v NMP and 90% v/v PEG300.
Dosages ≤30 mg/kg
Administration Administered via p.o.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Martiny-Baron G, et al. Angiogenesis. 2010, 13(3), 259-267.

Chemical Information

Download NVP-BHG712 SDF
Molecular Weight (MW) 503.48
Formula

C26H20F3N7O

CAS No. 940310-85-0
Storage 3 years -20℃powder
2 years -80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 101 mg/mL (200.6 mM)
Ethanol 3 mg/mL (5.95 mM)
Water <1 mg/mL
In vivo NMP+polyethylene glycol 300 (10+90, v+v) 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 4-methyl-3-(1-methyl-6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)-N-(3-(trifluoromethyl)phenyl)benzamide

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Ephrin receptor Products

Recently Viewed Items

Tags: buy NVP-BHG712 | NVP-BHG712 supplier | purchase NVP-BHG712 | NVP-BHG712 cost | NVP-BHG712 manufacturer | order NVP-BHG712 | NVP-BHG712 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us